Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis

Overview

About this study

The purpose of this study is to determine the prevalence of TTR-CA in a community-based cohort of moderate and severe aortic stenosis patients using 99mTc-PYP single-photon positive emission computed tomography with computed tomography (SPECT/CT).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Resident of Southeastern Minnesota (Olmsted, Dodge, Fillmore, Mower, Freeborn, Wabasha, or Steele County).
  • Age ≥ 75 years old.
  • Current diagnosis of moderate or severe aortic stenosis by most recent (within 6 months at most) echocardiogram as defined by:
    • Moderate Aortic Stenosis (AS): 1.0 cm^2 < aortic valve area (AVA) ≤ 1.5 cm^2;
    • Severe AS: AVA ≤ 1.0 cm^2.

Exclusion Criteria:

  • Any cardiac surgery or major chest trauma within 4 weeks of pyrophosphate (PYP) scan (or myocardial infarct imaging).
  • Myocardial infarction within 4 weeks of PYP scan defined by typical angina, EKG changes and significant change in serial troponins.
    • Note that chronic troponin elevation is extremely common in cardiac amyloidosis.
  • Prior or current exposure to Plaquenil (Hydroxychloroquine).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Omar Abou Ezzeddine, M.D., M.S.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20511558

Mayo Clinic Footer